Pharmaceuticals & Biotech Belgian Community

argenx is betting that its lead drug VYVGART can move beyond one rare disease and become a platform treatment across several autoimmune conditions. The upside comes from a steady stream of upcoming study results and new uses, but the story can also break if trials disappoint or drug-pricing pressure intensifies.Read more

UCB is pushing into hard-to-treat brain and immune diseases with new medicines, and early signs suggest these launches could keep growth going even as older drugs face more competition. See what could help the company scale up—and what could trip it up, from tougher pricing talks to drug patents running out.Read more

argenx leans heavily on one standout autoimmune medicine, and the next set of late-stage trial results and label expansions could determine whether it becomes a multi-product growth story. But rising competition and tougher reimbursement rules may squeeze what the company keeps from each sale, making the path ahead less straightforward than recent success suggests.Read more

Key Takeaways Rapid adoption of innovative therapies and expanded indications position UCB for sustained, above-industry revenue and earnings growth amid rising global demand for specialty treatments. Ongoing digitalization, operational leverage, and a shift to higher-margin products are boosting profitability, setting the stage for continued margin expansion and market share gains.Read more

Key Takeaways Rapid Vyvgart adoption, expanded indications, and accelerated self-administration are driving market expansion, revenue growth, and margin improvement well beyond initial expectations. Advancements in drug discovery and strong financial position enable swift pipeline development, supporting long-term leadership and outperformance in rare autoimmune biologics.Read more

Key Takeaways Pricing pressures, loss of exclusivity on key drugs, and rising regulatory barriers threaten revenue growth, profitability, and UCB's ability to sustain its branded market share. Limited pipeline diversity and slow digital transformation increase vulnerability to clinical setbacks, shifting market trends, and diminished long-term competitiveness.Read more

Key Takeaways Reliance on Vyvgart and vulnerability to biosimilar competition risk future revenue, margin stability, and long-term market share. Growing regulatory, pricing, and supply chain pressures threaten profitability and the ability to meet international expansion goals.Read more

Catalysts About MDxHealth MDxHealth provides precision molecular diagnostics that guide urology clinicians and patients through the full prostate cancer diagnostic pathway. What are the underlying business or industry changes driving this perspective?Read more